Thursday, 28 December 2017

PROMISING GENE THERAPY IN TREATMENT OF MALIGNANT MESOTHELIOMA

Modified, nonneurovirulent herpes simplex viruses (HSVs) have shown promise in treatment of brain tumors. However, HSV-1 can infect and cause disintegration of a wide variety of cell types. HSV-1716, a mutant of the virus lacking both copies of the gene coding ICP-34.5, can effectively treat a localized intraperitoneal malignancy. Human malignant mesothelioma cells supported the growth of HSV-1716 and efficiently disintegrated in vitro. Intraperitoneal injection of HSV-1716 into animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy, without dissemination or persistence, after intraperitoneal injection into mice bearing human tumors.

These findings suggest that this virus may be efficacious and safe for use in localized human malignancies of non-neural origin such as malignant mesothelioma. "Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma", Kucharczyk, et al.., Cancer Research, 57(3):466-71, February 1, 1997. Modified, nonneurovirulent herpes simplex viruses (HSVs) have shown promise in treatment of brain tumors.

 However, HSV-1 can infect and cause disintegration of a wide variety of cell types. HSV-1716, a mutant of the virus lacking both copies of the gene coding ICP-34.5, can effectively treat a localized intraperitoneal malignancy. Human malignant mesothelioma cells supported the growth of HSV-1716 and efficiently disintegrated in vitro. Intraperitoneal injection of HSV-1716 into animals with established tumor nodules reduced tumor burden and significantly prolonged survival in an animal model of non-central nervous system-localized human malignancy, without dissemination or persistence, after intraperitoneal injection into mice bearing human tumors. These findings suggest that this virus may be efficacious and safe for use in localized human malignancies of non-neural origin such as malignant mesothelioma. "Use of a 'replication-restricted' herpes virus to treat experimental human malignant mesothelioma", Kucharczyk, et al.., Cancer Research, 57(3):466-71, February 1, 1997.

PROMISING GENE THERAPY IN TREATMENT OF MALIGNANT MESOTHELIOMA Rating: 4.5 Diposkan Oleh: ABD KADIR Rusdi

Categories

canada (3) cancer (53) women (2)

Popular Posts